Phoenix Molecular Designs and WuXi STA Reach Drug Supply Milestone to Support Phase I/Ib Study of PMD-026 for TNBC

Written by Guest User

Jun. 04
2019

VANCOUVER, British Columbia and SAN DIEGO, June 4, 2019 - In March 2018, PhoenixMD and STA Pharmaceutical (WuXi STA) entered into a major manufacturing agreement, and have since produced a multi kilogram drug supply for PMD-026 under GMP manufacturing practices. This represents a significant milestone, accelerating PhoenixMD's Phase I readiness.

Read the story  here

Guest User
Previous

Phoenix Molecular Designs has been granted the Canadian patent titled "Methods of Inhibiting RSK for Treatment of Breast Cancer."
Next

REDUCING R(I)SK IN TNBC